Log In Sign up
The largest database of trusted experimental protocols
> Procedures > Laboratory Procedure > Nucleic Acid Amplification Tests

Nucleic Acid Amplification Tests

Nucleic Acid Amplification Tests (NAATs) are a class of molecular diagnostic assays that utilize various techniques to detect and amplify specific genetic sequences, enabling the identification of pathogens, infectious agents, or other targets of interest with high sensitivity and specificity.
These tests play a crucial role in the diagnosis, monitoring, and management of a wide range of diseases and conditions.
NAATs employ a variety of methodologies, including PCR (Polymerase Chain Reaction), RT-PCR (Reverse Transcription PCR), and isothermal amplification techniques, to exponentially amplify target nucleic acid sequences, allowing for the detection of even trace amounts of genetic material.
The ability to rapidly and accurately identify the presence of specific nucleic acid sequences makes NAATs invaluable tools in clinical settings, research, and public health surveillance.
Continous advancements in NAAT technologies, including the development of automated, point-of-care platforms, have expanded their applications and accessibility, empowering healthcare providers to make timely and informed decisions for patient care.

Most cited protocols related to «Nucleic Acid Amplification Tests»

1
Efficacy of BNT162b2 against COVID-19
Cited 101 times
The first primary end point was the efficacy of BNT162b2 against confirmed Covid-19 with onset at least 7 days after the second dose in participants who had been without serologic or virologic evidence of SARS-CoV-2 infection up to 7 days after the second dose; the second primary end point was efficacy in participants with and participants without evidence of prior infection. Confirmed Covid-19 was defined according to the Food and Drug Administration (FDA) criteria as the presence of at least one of the following symptoms: fever, new or increased cough, new or increased shortness of breath, chills, new or increased muscle pain, new loss of taste or smell, sore throat, diarrhea, or vomiting, combined with a respiratory specimen obtained during the symptomatic period or within 4 days before or after it that was positive for SARS-CoV-2 by nucleic acid amplification–based testing, either at the central laboratory or at a local testing facility (using a protocol-defined acceptable test).
Major secondary end points included the efficacy of BNT162b2 against severe Covid-19. Severe Covid-19 is defined by the FDA as confirmed Covid-19 with one of the following additional features: clinical signs at rest that are indicative of severe systemic illness; respiratory failure; evidence of shock; significant acute renal, hepatic, or neurologic dysfunction; admission to an intensive care unit; or death. Details are provided in the protocol.
An explanation of the various denominator values for use in assessing the results of the trial is provided in Table S1 in the Supplementary Appendix, available at NEJM.org. In brief, the safety population includes persons 16 years of age or older; a total of 43,448 participants constituted the population of enrolled persons injected with the vaccine or placebo. The main safety subset as defined by the FDA, with a median of 2 months of follow-up as of October 9, 2020, consisted of 37,706 persons, and the reactogenicity subset consisted of 8183 persons. The modified intention-to-treat (mITT) efficacy population includes all age groups 12 years of age or older (43,355 persons; 100 participants who were 12 to 15 years of age contributed to person-time years but included no cases). The number of persons who could be evaluated for efficacy 7 days after the second dose and who had no evidence of prior infection was 36,523, and the number of persons who could be evaluated 7 days after the second dose with or without evidence of prior infection was 40,137.
Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J.L., Pérez Marc G., Moreira E.D., Zerbini C., Bailey R., Swanson K.A., Roychoudhury S., Koury K., Li P., Kalina W.V., Cooper D., Frenck RW J.r., Hammitt L.L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D.B., Mather S., Dormitzer P.R., Şahin U., Jansen K.U, & Gruber W.C. (2020). Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. The New England Journal of Medicine.
Publication 2020
Age Groups Ageusia BNT162B2 Chills Cough COVID 19 Diarrhea Dyspnea Fever Infection Kidney Myalgia Nucleic Acid Amplification Tests Placebos Respiratory Failure Respiratory Rate Safety SARS-CoV-2 Sense of Smell Shock Sore Throat Vaccines
2
Comparative Evaluation of Tuberculosis Diagnostic Tests
Cited 33 times
Patients meeting the clinical eligibility criteria were asked to provide three sputum specimens over a 2-day period (two spot samples and one obtained in the morning) (Fig. 1). In a random fashion, two of the three samples were processed with N-acetyl-l-cysteine and sodium hydroxide (NALC–NaOH),14 followed by centrifugation, and then were resuspended in 1.5 ml of phosphate buffer and subjected to microscopy with Ziehl–Neelsen staining, and cultivation on solid medium (egg-based Löwenstein–Jensen15 or 7H11,16 (link) with the latter medium used only in Durban) and liquid medium (BACTECMGIT [mycobacteria growth indicator tube] 960 culture; BD Microbiology Systems), and the MTB/RIF test. The third sputum sample was tested directly by Ziehl–Neelsen microscopy and the MTB/RIF test without NALC–NaOH decontamination.
The first positive culture from each specimen underwent confirmation of M. tuberculosis species by MPT64 antigen detection (Capilia TB, Tauns Laboratories)17 (link) and indirect drug-susceptibility testing with the proportion method on Löwenstein–Jensen medium (for sites in Lima, Durban, and Baku) or MGIT SIRE18 (for sites in Cape Town and Mumbai). For three sites, conventional nucleic acid–amplification testing was carried out on DNA that was extracted from the NALC–NaOH centrifugation pellet of the first sputum sample with the use of Cobas Amplicor MTB (Roche) (in Cape Town and Mumbai) or ProbeTec ET MTB Complex Direct Detection Assay (BD) (in Baku), according to the manufacturer's instructions. At three sites, drug-resistant genotyping was carried out by line-probe assay with the use of the Geno-type MTBDRplus assay (Hain Lifescience) performed from culture isolates (in Baku) or from the NALC–NaOH pellet of the second sputum sample (in Cape Town and Durban), according to the manufacturer's instructions, except that smear-negative specimens were also tested.
All participating laboratories were quality-assured reference laboratories. Study laboratories for four sites were located within 5 km of the enrollment clinic and tested samples within 2 days after collection. Sputum samples from Baku were shipped to the German National Reference Laboratory in Borstel for testing 1 to 5 days after collection.
Repeat tuberculosis analyses (smear, culture, MTB/RIF test, radiography, and clinical workup) were performed in patients who had smear- and culture-negative samples if the MTB/RIF test or other nucleic acid–amplification test was positive or if the patient was selected by the central database as a random control for follow-up. The final diagnosis for patients undergoing repeat analyses was established on the basis of conventional laboratory results and clinical information by clinical review committees composed of three local tuberculosis clinicians. HIV results were obtained by review of clinical records and were available for only a subgroup of patients. Bias was minimized through blinding, since technicians performing molecular and reference tests were not aware of the results of other tests. The interpretation of data from MTB/RIF tests was software-based and independent of the user. Clinical teams and review committees did not have access to nucleic acid–amplification test results. All study coordinators received lists of patients for follow-up but not the reasons for follow-up.
Boehme C.C., Nabeta P., Hillemann D., Nicol M.P., Shenai S., Krapp F., Allen J., Tahirli R., Blakemore R., Rustomjee R., Milovic A., Jones M., O'Brien S.M., Persing D.H., Ruesch-Gerdes S., Gotuzzo E., Rodrigues C., Alland D, & Perkins M.D. (2010). Rapid Molecular Detection of Tuberculosis and Rifampin Resistance. The New England journal of medicine, 363(11), 1005-1015.
Publication 2010
Acetylcysteine Antigens Biological Assay Buffers Centrifugation Decontamination Diagnosis Eligibility Determination Genotype Microscopy Mycobacterium Mycobacterium tuberculosis Nucleic Acid Amplification Tests Patients Pharmaceutical Preparations Phosphates Sodium Hydroxide Sputum Substance Abuse Detection Susceptibility, Disease Tuberculosis X-Rays, Diagnostic
3
Safety and Immunogenicity of BNT162 Vaccines
Cited 16 times
We assessed the safety and immunogenicity of three dose levels of BNT162b1 and BNT162b2. Healthy adults 18 to 55 years of age or 65 to 85 years of age were eligible for inclusion. Key exclusion criteria were known infection with human immunodeficiency virus, hepatitis C virus, or hepatitis B virus; an immunocompromised condition; a history of autoimmune disease; a previous clinical or microbiologic diagnosis of Covid-19; the receipt of medications intended to prevent Covid-19; any previous coronavirus vaccination; positive test for SARS-CoV-2 IgM or IgG at the screening visit; and positive nasal-swab results on a SARS-CoV-2 nucleic acid amplification test within 24 hours before the receipt of trial vaccine or placebo.
BioNTech was the regulatory sponsor of the trial. Pfizer was responsible for the trial design; for the collection, analysis, and interpretation of the data; and for the writing of the report. The corresponding author had full access to all the data in the trial and had final responsibility for the decision to submit the manuscript for publication. All the trial data were available to all the authors.
Walsh E.E., Frenck RW J.r., Falsey A.R., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M.J., Bailey R., Swanson K.A., Li P., Koury K., Kalina W., Cooper D., Fontes-Garfias C., Shi P.Y., Türeci Ö., Tompkins K.R., Lyke K.E., Raabe V., Dormitzer P.R., Jansen K.U., Şahin U, & Gruber W.C. (2020). Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. The New England Journal of Medicine.
Publication 2020
Adult Antigens Autoimmune Diseases BNT-162B1 BNT162B2 B virus, Hepatitis Coronavirus COVID 19 Diagnosis Hepatitis C virus HIV Infections Nose Nucleic Acid Amplification Tests Pharmaceutical Preparations Placebos Safety SARS-CoV-2 Vaccination Vaccines
4
WHO Standard Calibration for Malaria NAT Assays
Cited 15 times
The WHO international standard for P. falciparum DNA nucleic acid amplification technology (NAT) assays, obtained from the National Institute for Biological Standards and Control (NIBSC; Hertfordshire, United Kingdom) was used as the calibration reference reagent for of the Plasmodium spp. and P. falciparum assays. The standard consists of a freeze-dried preparation of whole blood collected by exchange transfusion from a patient infected with P. falciparum. Following NIBSC recommendations, this lyophilized material was suspended in 500 µl of sterile, nuclease-free water to a final concentration of 1×109 IU/ml, which corresponds to a parasitemia of 9.79 parasites/100 red blood cells [11] . The parasite density of the NAT assays after reconstitution was estimated to be 469,920 parasites/µl, based on the average red blood cell count [from uninfected donor] of 4.8×106 RBC/µl. Unless otherwise indicated, fresh uninfected whole blood was used as a diluent to prepare serial dilutions. The uninfected whole blood was obtained from donors from Washington DC metropolitan area under WRAIR approved protocol. After reconstitution, genomic DNA was extracted with the EZ1 DNA blood kit on the EZ1 Advanced XL automated sample purification system (Qiagen, Valencia, CA) as recommended by the manufacturer.
Kamau E., Alemayehu S., Feghali K.C., Saunders D, & Ockenhouse C.F. (2013). Multiplex qPCR for Detection and Absolute Quantification of Malaria. PLoS ONE, 8(8), e71539.
Full text: Click here
Publication 2013
Biological Assay Biopharmaceuticals BLOOD Donors Erythrocyte Count Exchange Transfusion, Whole Blood Freezing Genome Nucleic Acid Amplification Tests Parasitemia Parasites Patients Plasmodium Sterility, Reproductive Technique, Dilution Tissue Donors
5
Comprehensive HIV Cohort Identification in British Columbia
Cited 15 times
The cohort of interest for analysis included all HIV positive persons aged 18 months of age or older who tested HIV positive or otherwise had some HIV-related record in at least one of the databases described in Table 1 between January 1st, 1995 and March 31st, 2010. Individuals were included if they were captured in the CDC HIV surveillance database (persons with a documented positive HIV test) or the CfE treatment registry (having at least one plasma viral load/CD4 test and/or receiving antiretroviral medications) or if they were identified within health administrative datasets held by the MoH (Medical Services Plan (MSP) database; Discharge Abstract Database (DAD)) as having received care for an HIV- or AIDS-related medical condition on at least one occasion. Additional linkages to provincial drug dispensation (BC PharmaNet database) and mortality records (BC Vital statistics database) were also available and employed in subsequent analyses to refine the cohort.
Individuals meeting the provincial HIV case definition, and testing HIV-positive for the first time in British Columbia, were included from the CDC database. This entails detection of HIV antibody by screening test (i.e., ELISA or Point of Care HIV test) followed by positive confirmatory test (i.e., Western Blot or Nucleic Acid Amplification Test), or Detection of HIV nucleic acid (RNA or DNA) or detection of p24 antigen with confirmation by neutralization assay, or isolation of HIV in culture. Tests were excluded when an individual chose non-nominal reporting as prescribed in the provincial Communicable Disease Regulation, where identifiers were insufficient for linkage. Individuals were identified in MoH datasets using ICD-9/10 diagnostic codes associated with HIV/AIDS (MSP: any ICD-9/10 code starting with ‘042’, ‘043’, ‘044’, ‘V08’, ICD-9 code 795.71 or ICD-9 codes starting with 795.8; DAD: all previous codes, in addition to ICD-10-CA codes B24, R75, Z21, B20–B23).
Database linkage was executed by data stewards in each collaborating agency and coordinated by the Vancouver Coastal Health Authority. Clients were matched to the client registry by provincial health number (PHN). PHNs are mandatory for all BC residents [23] , and are not available to tourists or other non-residents. The final de-identified datasets were provided to the analysis team (CfE). A privacy impact assessment was completed for this study. Ethical approval was obtained through the UBC Behavioural Research Ethics Board (no. H08-02095).
Nosyk B., Colley G., Yip B., Chan K., Heath K., Lima V.D., Gilbert M., Hogg R.S., Harrigan P.R, & Montaner J.S. (2013). Application and Validation of Case-Finding Algorithms for Identifying Individuals with Human Immunodeficiency Virus from Administrative Data in British Columbia, Canada. PLoS ONE, 8(1), e54416.
Full text: Click here
Publication 2013
Acquired Immunodeficiency Syndrome Antigens ARID1A protein, human Biological Assay Communicable Diseases Diagnosis Enzyme-Linked Immunosorbent Assay HIV Antibodies isolation Nucleic Acid Amplification Tests Nucleic Acids Patient Discharge Pharmaceutical Preparations Plasma Point-of-Care Testing Postherpetic Neuralgia Western Blotting

Most recents protocols related to «Nucleic Acid Amplification Tests»

1
Vaccination Efficacy Against Delta Variant
All patients were treated by the medical team of the First Affiliated Hospital of Xi’an Jiaotong University between 20 December 2021, and 20 January 2022. The eligible discharged patients were screened in this retrospective study (Figure 1), and patients younger than 5 years old were excluded. Patients with incomplete and inaccurate baseline data were also excluded from this study. All patients were confirmed to infect with SARS-CoV-2 delta variant by Xi’an CDC (Center for Disease Control and Prevention). There were 31 patients who did not receive any vaccination (non-vaccination group, NV), 21 patients who received only one-dose vaccination (one-vaccination group, OV) and 60 patients who received two- or three-dose vaccination (two-vaccination group, TV). All vaccinated patients received inactivated vaccines (inactivated SARS-CoV-2 vaccine CoronaVac, and aluminium hydroxide as adjuvant. Sinovac life sciences Co. Ltd.). All patients underwent nasopharyngeal swab sample collection according to the national guidelines [16 (link)] and were diagnosed via SARS-CoV-2 nucleic acid amplification tests, and the results were confirmed by the Xi’an Center for Disease Control and Prevention. This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi’an Jiaotong University, and all patients provided written informed consent. All research methods were carried out in compliance with the relevant declarations of medical ethics and the Declaration of Helsinki.
Li H., Li Y., Liu J., Liu J., Han J, & Yang L. (2023). Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients. Annals of Medicine, 55(1), 419-427.
Full text: Click here
Publication 2023
CoronaVac Ethics Committees, Clinical Hydroxide, Aluminum Nasopharynx Nucleic Acid Amplification Tests Patients Pharmaceutical Adjuvants SARS-CoV-2 SARS-CoV-2 B.1.617.2 variant SARS-CoV-2 inactivated vaccines Specimen Collection Vaccination Vaccines, Inactivated Youth
2
SARS-CoV-2 Viral Load and Antibody Detection
SARS-CoV-2 nucleic acid expression was detected with SARS-CoV-2 virus kits via quantitative reverse transcription polymerase chain reaction (2019-nCoV Nucleic acid detection Kit, Daan Gene, Guangzhou, China) according to the national guideline and the manufacturer’s instructions, and all patients were examined daily during hospitalization. The conditions for SARS-CoV-2 nucleic acid amplification were 50 °C for 15 min, 95 °C for 15 min, followed by 45 cycles of 94 °C for 15 s and 55 °C for 45 s. Positive detection was defined as a cycle threshold (Ct value) less than 40(500 copies/ml), and the test procedure was carried out in strict accordance with the protocol. A patient’s viral load was defined as the patient’s lowest Ct value during hospitalization, and the time to peak viral load was defined as the time from the first positive SARS-CoV-2 test to the lowest Ct value during hospitalization. The incubation period was defined as the number of days from contact exposure to the onset of a positive nucleic acid result.
Serum antibodies (anti-Spike IgG and IgM) against SARS-CoV-2 were detected via a commercial ELISA kit (SARS-CoV-2 Ig G and SARS-CoV-2 IgM, Maccura Biotechnology Co., Ltd., Chengdu, China) according to the manufacturer’s instructions, and the antibodies were detected at admission, day 7, day 10, day 14 and at discharge. Briefly, 96-well plates were coated with purified SARS-CoV-2 antigen in phosphate buffer overnight at 4 °C in physiological saline (PBS). We added 10 µl of each serum sample to a reaction plate, mixed it with 50 µl magnetic beads and 50 µl buffer, incubated it in the reaction plate for 10 min and then washed it. Then, we added 100 µl acridine ester-labeled recombinant magnetic beads and incubated them in the reaction plate for 10 min. After washing, we added the substrate solution and mixed it well to detect the luminescence signal value. The assay detects antibodies to the spike protein of SARS-CoV-2 with a cut-off (CO) value of <1.0 for negative results and the value ≥1.0 were defined as positive, the final value of the test was calculated with the optical density value of the sample/CO value.
Li H., Li Y., Liu J., Liu J., Han J, & Yang L. (2023). Vaccination reduces viral load and accelerates viral clearance in SARS-CoV-2 Delta variant-infected patients. Annals of Medicine, 55(1), 419-427.
Full text: Click here
Publication 2023
Acridines anti-IgG Antibodies Antigens Biological Assay Buffers Enzyme-Linked Immunosorbent Assay Esters Genes Hospitalization Luminescence Nucleic Acid Amplification Tests Nucleic Acids Patient Discharge Patients Phosphates physiology Reverse Transcriptase Polymerase Chain Reaction Saline Solution SARS-CoV-2 Serum spike protein, SARS-CoV-2
3
Rapid TRC for Influenza Detection
For TRCsatFLU, we soaked a new swab in a gargle sample for 5 s, and the swab containing the gargle solution was mixed with 1 mL extraction buffer containing surfactant, and it was infected into a single-use cartridge that contains all the elements required for rapid TRC. Nasopharyngeal swabs were mixed with 1 mL extraction buffer containing surfactant. Of the extraction buffer, 140 μL was aliquoted for RT-PCR, and the remaining 860 μL was injected into the TRCsatFLU cartridge. Next, the cartridge was set in TRCsat®, and nucleic acid amplification, detection, and determination of results were automatically performed in the instrument. The procedure of rapid TRC in TRCsat® is as follows: the samples were incubated at 52 °C for 1 min and then mixed 30 μL of the sample with a dry reagent containing enzymes, substrates, primers, and INAF probes and incubated at 46 °C to monitor fluorescence; it was automatically determined as positive when the fluorescence intensity ratio of the reaction solution exceeded 1.2. TRCsatFLU was designed to detect Influenza A(H1N1), A(H1N1)pdm09, A (H3N2), and B (Victoria and Yamagata lineages), but TRCsat® only showed the results with influenza A or B positive or influenza negative.
Kaku N., Urabe T., Iida T., Yun C., Nishida Y., Onitsuka Y., Hashiguchi K., Hirose K., Tomonaga A., Izumikawa K., Mukae H, & Yanagihara K. (2023). Gargle sample is an effective option in a novel fully automated molecular point-of-care test for influenza: a multicenter study. Virology Journal, 20, 41.
Full text: Click here
Publication 2023
Buffers Enzymes Fluorescence Mouthwashes Nasopharynx Nucleic Acid Amplification Tests Oligonucleotide Primers Reverse Transcriptase Polymerase Chain Reaction Surfactants Virus Vaccine, Influenza
4
SARS-CoV-2 RT-RAA Assay Evaluation

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2023
Biological Assay Buffers Enzymes Freezing Genes Hereditary Diseases magnesium acetate Medical Devices Nucleic Acid Amplification Tests Nucleocapsid Oligonucleotide Primers Oligonucleotides Rehydration RNA-Directed DNA Polymerase SARS-CoV-2
5
Yeast Growth on Diverse Carbohydrates
Tannin (gallotannin) was purchased from LOBA Chemie (Mumbai, India), and methyl gallate was purchased from Sigma (Steinheim, Germany). Ingredients such as peptone, yeast extract, malt extract, and carbon sources such as glucose, galactose, sucrose, maltose, lactose, raffinose, and trehalose were purchased from HiMedia (Nashik, India). The genomic DNA of yeast was extracted using a Wizard® Genomic DNA purification kit (Promega Corp., Madison, WI, United States). Nucleic acid amplifications were performed using TaKaRa Ex Taq® (Shiga, Japan). Other reagents and solvents were of analytical grade.
Kanpiengjai A., Kodchasee P., Unban K., Kumla J., Lumyong S., Khunnamwong P., Sarkar D., Shetty K, & Khanongnuch C. (2023). Three new yeast species from flowers of Camellia sinensis var. assamica collected in Northern Thailand and their tannin tolerance characterization. Frontiers in Microbiology, 14, 1043430.
Full text: Click here
Publication 2023
Carbon Galactose Genome Glucose Lactose Maltose methyl gallate Nucleic Acid Amplification Tests Peptones Promega Raffinose Saccharomyces cerevisiae Solvents Sucrose Tannins Trehalose

Top products related to «Nucleic Acid Amplification Tests»

1
Trizol reagent by Thermo Fisher Scientific
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
2
Xpert mtb rif by Cepheid
Sourced in United States, Germany
The Xpert MTB/RIF is a molecular diagnostic test developed by Cepheid. It is designed to detect the presence of Mycobacterium tuberculosis (MTB) and identify resistance to the antibiotic rifampicin (RIF) directly from sputum samples. The test utilizes real-time PCR technology to provide rapid and accurate results.
3
Aptima combo 2 assay by Hologic
Sourced in United States, New Zealand
The Aptima Combo 2 assay is a nucleic acid amplification test that detects the presence of Chlamydia trachomatis and Neisseria gonorrhoeae in clinical specimens. It is designed for use with the Hologic Panther system, a fully automated molecular diagnostic platform.
4
Dnase 1 by Merck Group
Sourced in United States, Germany, Switzerland, United Kingdom, Italy, Japan, Macao, Canada, Sao Tome and Principe, China, France, Australia, Spain, Belgium, Netherlands, Israel, Sweden, India
DNase I is a laboratory enzyme that functions to degrade DNA molecules. It catalyzes the hydrolytic cleavage of phosphodiester linkages in the DNA backbone, effectively breaking down DNA strands.
5
Sybr green realtime pcr master mix by Toyobo
Sourced in Japan, United States, China, Germany, Switzerland, Canada, Australia, Sweden
SYBR Green Realtime PCR Master Mix is a ready-to-use solution containing all the necessary components for real-time PCR amplification using the SYBR Green detection method. It includes a DNA polymerase, buffer, dNTPs, and SYBR Green I dye.
6
Revertra ace α first strand cdna synthesis kit by Toyobo
Sourced in Japan, China, United States
The ReverTra Ace-α First-Strand cDNA Synthesis Kit is a laboratory product designed for the reverse transcription of RNA to complementary DNA (cDNA). It provides the necessary components for the efficient conversion of RNA into cDNA, which is a crucial step in various molecular biology and genetic research applications.
7
Genexpert by Cepheid
Sourced in United States, Germany
The GeneXpert is a compact, automated system for molecular diagnostic testing. It is designed to perform rapid, real-time PCR (Polymerase Chain Reaction) analysis to detect the presence of specific nucleic acid sequences. The GeneXpert system integrates sample preparation, nucleic acid amplification, and detection in a single fully-automated process.
8
Da7600 real time nucleic acid amplification fluorescence detection system by Bio-Rad
Sourced in United States
The DA7600 Real-time Nucleic Acid Amplification Fluorescence Detection System is a laboratory instrument designed for real-time monitoring and analysis of nucleic acid amplification processes. The system utilizes fluorescence detection to track the amplification of target nucleic acid sequences in real-time. The core function of the DA7600 is to provide a platform for sensitive and precise measurement of nucleic acid amplification, allowing researchers to quantify and characterize target molecules during the amplification process.
9
Aptima by Hologic
Sourced in United States
Aptima is a diagnostic laboratory equipment product developed by Hologic. It is designed to perform nucleic acid amplification testing for the detection of various infectious agents. The core function of Aptima is to assist healthcare professionals in the diagnosis and management of infectious diseases.
10
Cfx96 by Bio-Rad
Sourced in United States, China, Japan, Germany, France, United Kingdom, Canada, Singapore, Italy, Sweden, Estonia, Israel
The CFX96 is a real-time PCR detection system manufactured by Bio-Rad. It is designed for quantitative gene expression analysis and nucleic acid detection. The system includes a thermal cycler and an optical detection module to enable real-time monitoring of PCR reactions.

More about "Nucleic Acid Amplification Tests"

Nucleic Acid Amplification Tests (NAATs) are a powerful class of molecular diagnostic assays that utilize various techniques to detect and amplify specific genetic sequences.
These tests play a crucial role in the diagnosis, monitoring, and management of a wide range of diseases and conditions.
NAATs employ a variety of methodologies, including PCR (Polymerase Chain Reaction), RT-PCR (Reverse Transcription PCR), and isothermal amplification techniques, to exponentially amplify target nucleic acid sequences, allowing for the detection of even trace amounts of genetic material.
This makes them invaluable tools in clinical settings, research, and public health surveillance.
Continous advancements in NAAT technologies, including the development of automated, point-of-care platforms like GeneXpert and the DA7600 Real-time Nucleic Acid Amplification Fluorescence Detection System, have expanded their applications and accessibility.
Healthcare providers can now make timely and informed decisions for patient care using these advanced molecular diagnostic assays.
NAATs can be used to detect a variety of pathogens, infectious agents, and other targets of interest with high sensitivity and specificity.
This includes the detection of tuberculosis (Xpert MTB/RIF), sexually transmitted infections (Aptima Combo 2 assay), and more.
The use of reagents like TRIzol and enzymes like DNase I further enhance the effectiveness of these tests.
Real-time PCR platforms, such as the CFX96, utilize SYBR Green or other fluorescent dyes to monitor the amplification of target sequences in real-time, providing rapid and accurate results.
Complementary technologies, like the ReverTra Ace-α First-Strand cDNA Synthesis Kit, enable the conversion of RNA to cDNA for downstream NAAT analysis.
Discover the power of PubCompare.ai, your AI-driven platform for optimizing Nucleic Acid Amplification Test protocols.
Easily locate the best protocols from literature, pre-prints, and patents, using our advanced AI-driven comparison tools.
Identify the most effective products and streamline your testing process.
Experiance the future of nucleic acid amplification today with PubCompare.ai.